Muthoni G. Kamau
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Muthoni G. Kamau.
Bioorganic & Medicinal Chemistry Letters | 2008
Lalgudi S. Harikrishnan; Muthoni G. Kamau; Timothy Herpin; George C. Morton; Yalei Liu; Christopher B. Cooper; Mark E. Salvati; Jennifer X. Qiao; Tammy C. Wang; Leonard P. Adam; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Ramakrishna Seethala; Tara L. Peterson; David S. Nirschl; Arthur V. Miller; Carolyn A. Weigelt; Kingsley K. Appiah; Jonathan O’Connell; R. Michael Lawrence
2-Arylbenzoxazole 5 was identified as a hit from a fluorescence-based high-throughput screen for CETP inhibitors. The synthesis and SAR investigation employing array synthesis of the A- and B-rings are described.
Journal of Medicinal Chemistry | 2012
Lalgudi S. Harikrishnan; Heather Finlay; Jennifer X. Qiao; Muthoni G. Kamau; Ji Jiang; Tammy C. Wang; James C. B. Li; Christopher B. Cooper; Michael A. Poss; Leonard P. Adam; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Paul G. Sleph; Richard Yang; Doree Sitkoff; Michael A. Galella; David S. Nirschl; Katy Van Kirk; Arthur V. Miller; Christine Huang; Ming Chang; Xue-Qing Chen; Mark E. Salvati; Ruth R. Wexler; R. Michael Lawrence
A series of diphenylpyridylethanamine (DPPE) derivatives was identified exhibiting potent CETP inhibition. Replacing the labile ester functionality in the initial lead 7 generated a series of amides and ureas. Further optimization of the DPPE series for potency resulted in the discovery of cyclopentylurea 15d, which demonstrated a reduction in cholesterol ester transfer activity (48% of predose level) in hCETP/apoB-100 dual transgenic mice. The PK profile of 15d was suboptimal, and further optimization of the N-terminus resulted in the discovery of amide 20 with an improved PK profile and robust efficacy in transgenic hCETP/apoB-100 mice and in hamsters. Compound 20 demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemeterized rats despite sustained high exposures.
Bioorganic & Medicinal Chemistry Letters | 2003
Rakesh K. Jain; Muthoni G. Kamau; Chunguang Wang; Robert Ippolito; Huiming Wang; Richard Dulina; Jan Anderson; David Gange; Michael J. Sofia
The regiospecific syntheses of six monosaccharide scaffolds, 1-6, containing a carboxylic acid, an azido and a free hydroxyl group were accomplished through the utilization of a key intermediate, namely, methyl 3-azido-3-deoxy-beta-D-glucopyranoside (10). Scaffold 2 was also used in generating combinatorial libraries using solid-phase methodologies.
Bioorganic & Medicinal Chemistry Letters | 2012
Michael M. Miller; Yalei Liu; Ji Jiang; James A. Johnson; Muthoni G. Kamau; David S. Nirschl; Yufeng Wang; Lalgudi S. Harikrishnan; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Ramakrishna Seethala; Tara L. Peterson; Tatyana Zvyaga; Jun Zhang; Christine Huang; Ruth R. Wexler; Michael A. Poss; R. Michael Lawrence; Leonard P. Adam; Mark E. Salvati
A novel series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein is described. Optimization of the urea moiety, particularly by incorporation of fluorine, is explored to balance in vitro metabolic stability with CETP potency in the whole plasma assay.
Bioorganic & Medicinal Chemistry Letters | 2011
Lalgudi S. Harikrishnan; Muthoni G. Kamau; Honghe Wan; Jennifer Inghrim; Kurt Zimmermann; Xiaopeng Sang; Harold Mastalerz; Walter Lewis Johnson; Guifen Zhang; Louis J. Lombardo; Michael A. Poss; George L. Trainor; John S. Tokarski; Matthew V. Lorenzi; Dan You; Marco M. Gottardis; Kathy F. Baldwin; Jonathan Lippy; David S. Nirschl; Ruhui Qiu; Arthur V. Miller; Javed Khan; John S. Sack; Ashok V. Purandare
SAR studies of pyrrolo[1,2-f]triazines as JAK2 inhibitors is presented. Achieving JAK2 inhibition selectively over JAK3 is discussed.
Journal of Medicinal Chemistry | 2015
Jennifer X. Qiao; Tammy C. Wang; Leonard P. Adam; Alice Ye A. Chen; David S. Taylor; Richard Yang; Shaobin Zhuang; Paul G. Sleph; Julia P. Li; Danshi Li; Xiaohong Yin; Ming Chang; Xue-Qing Chen; Hong Shen; Jianqing Li; Daniel J. Smith; Dauh-Rurng Wu; Leslie Leith; Lalgudi S. Harikrishnan; Muthoni G. Kamau; Michael M. Miller; Donna M. Bilder; Richard Rampulla; Yi-Xin Li; Carrie Xu; R. Michael Lawrence; Michael A. Poss; Paul Levesque; David A. Gordon; Christine Huang
Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe the lead optimization efforts resulting in the discovery of a series of triphenylethanamine (TPE) ureas and amides as potent and orally available CETP inhibitors. Compound 10g is a potent CETP inhibitor that maximally inhibited cholesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrapib (1) in moderately-fat fed hamsters. In contrast to the off-target liabilities with 1, no blood pressure increase was observed with 10g in rat telemetry studies and no increase of aldosterone synthase (CYP11B2) was detected in H295R cells. On the basis of its preclinical profile, compound 10g was advanced into preclinical safety studies.
Bioorganic & Medicinal Chemistry Letters | 2014
Yufeng Wang; Wu Yang; Heather Finlay; Lalgudi S. Harikrishnan; Ji Jiang; Muthoni G. Kamau; Katy Van Kirk; David S. Nirschl; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Paul G. Sleph; Richard Yang; Christine Huang; Leonard P. Adam; R. Michael Lawrence; Ruth R. Wexler; Mark E. Salvati
A series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein with aminoheterocycles appended onto the N-terminus of the chemotype were explored as urea mimetics. Potent compounds were discovered and were further optimized to improve metabolic stability and PXR transactivation profile.
ACS Combinatorial Science | 2009
Jacques Y. Roberge; Lalgudi S. Harikrishnan; Muthoni G. Kamau; Zheming Ruan; Katy Van Kirk; Yalei Liu; Christopher B. Cooper; Michael A. Poss; John K. Dickson; Ashvinikumar V. Gavai; Sam T. Chao; Leslie Leith; Mark S. Bednarz; Arvind Mathur; Ramesh Kakarla; Dora M. Schnur; Roy J. Vaz; R. Michael Lawrence
A G-Protein-coupled receptor-targeted library of aryloxypropanolamines and aryloxybutanolamines was efficiently executed using a novel, polymer-supported acyclic acetal linker, producing compounds in good yields and purities.
Bioorganic & Medicinal Chemistry Letters | 2016
Ji Jiang; Heather Finlay; James A. Johnson; Lalgudi S. Harikrishnan; Muthoni G. Kamau; Jennifer X. Qiao; Tammy C. Wang; Leonard P. Adam; David S. Taylor; Richard Yang; Paul G. Sleph; Alice Ye A. Chen; Xiaohong Yin; Ruth R. Wexler; Mark E. Salvati
Hydroxyl 1,2-diphenylethanamine analogs were identified as potent inhibitors of cholesterol ester transfer protein (CETP), a therapeutic target to raise HDL cholesterol. In an effort to improve the pharmaceutical properties in the previously disclosed DiPhenylPyridineEthanamine (DPPE) series, polar groups were introduced to the N-linked quaternary center. Optimization of analogues for potency, in vitro liability profile and efficacy led to identification of lead compound 16 which demonstrated robust pharmacodynamic effects in human CETP/apo-B100 dual transgenic mice.
Journal of Medicinal Chemistry | 1999
Michael J. Sofia; Nigel M. Allanson; Nicole T. Hatzenbuhler; Rakesh K. Jain; Ramesh Kakarla; Natan Kogan; Rui Liang; Dashan Liu; Domingos J. Silva; Huiming Wang; David Gange; Jan Anderson; Anna Chen; Feng Chi; Richard Dulina; Buwen Huang; Muthoni G. Kamau; Chunguang Wang; Eugene R. Baizman; Arthur A. Branstrom; Neil Bristol; Robert Goldman; Kiho Han; Clifford B. Longley; Sunita Midha; Helena R. Axelrod